摘要
目的观察由羟基喜树碱(HCPT)为主,联合依托泊苷(VP16)、顺铂(PDD)和泼尼松(PDN)组成的HEPP方案治疗难治性非霍奇金淋巴瘤(NHL)的客观疗效和毒副反应。方法全组25例NHL患者,男性16例,女性9例,中位年龄55岁,均为复治病例。采用HEPP方案,即HCPT8mg/m2,静脉滴注,第1￣5天;VP16100mg/d,静脉滴注,第1￣5天,PDD20mg/d,静脉滴注,第1￣5天,PDN60mg/m2,口服,第1￣14天。28d为1个周期,连续用药2个周期以上,按WHO标准评价近期疗效,并每周期观察毒副反应。结果全组25例中,可以评价疗效的22例,获得完全缓解(CR)3例,部分缓解(PR)10例,稳定(SD)6例,进展(PD)3例,总有效率(CR+PR)60.0%。中位肿瘤进展时间(TTP)为6个月。血液学毒性是该方案的主要毒副作用,白细胞下降的发生率为48.0%,其中Ⅲ/Ⅳ度占24.0%;血小板下降的发生率为20.0%,Ⅲ/Ⅳ度占12.0%。恶心、呕吐反应多为Ⅰ/Ⅱ度,口腔炎、肝功能异常、便秘给予相应处理后均能在短期恢复。结论HEPP方案治疗难治性NHL的近期疗效满意,毒副作用可耐受,值得临床进一步观察使用。
Objective To observe the short-term efficacy and toxicity of HEPP regimen in treatment of refractory Non-Hodgkin＇s Lymphoma. Methods HEPP regimen： HCPT 8 mg/m^2 iv gtt d1 ～ dS, VP16 100 mg/d iv gtt d1～d5, PDD 20 mg/d iv gtt d1～d5, PDN 60 mg/m^2 po d1～d14. The chemotherapy was repeated every 4 weeks as a cycle.The clinical effect was evaluated after 2 cycles and toxicity was observed during every cycle. Results 25 patients were eligible for toxicity evaluation and 22 patients for clinical response evaluation. The objective response rate was 60.0 %, including three cases complete remission and ten cases partial remission. Six cases achieved stable disease and three cases progressive disease. The major toxicity was bone marrow suppression, including 24.0 % grade Ⅲ/Ⅳ leukopenia and 12.0 % grade Ⅲ/Ⅳ thrombocytopenia. The incidence of nausea/vomiting, mucositis and hepatic toxicity was low. Conclusion HEPP regimen can achieve a satisfy result in the treatment of refractory Non-Hodgkin＇s Lymphoma. It is low toxic and well tolerated.
出处
《肿瘤研究与临床》
CAS
2006年第3期158-160,共3页
Cancer Research and Clinic
